Connor, Clark & Lunn Investment Management (CC&L)’s BridgeBio Pharma BBIO Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-6,347	Closed	-$485K	–	1557
2025 Q4	$485K	Buy	+6,347	New	+$417K	﹤0.01%	1306
2025 Q2	–	Sell	-36,207	Closed	-$1.25M	–	1508
2025 Q1	$1.25M	Buy	+36,207	New	+$1.22M	0.01%	877
2024 Q4	–	Sell	-12,148	Closed	-$309K	–	1413
2024 Q3	$309K	Buy	+12,148	New	+$319K	﹤0.01%	1229
2022 Q4	–	Sell	-50,158	Closed	-$499K	–	1207
2022 Q3	$499K	Buy	50,158 +33,309	+198%	+$346K	﹤0.01%	820
2022 Q2	$153K	Sell	16,849 -351,105	-95%	-$2.94M	﹤0.01%	956
2022 Q1	$3.73M	Buy	+367,954	New	+$3.78M	0.02%	377

Other funds holding BBIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s BBIO Position: Q1 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of BridgeBio Pharma (BBIO) in Q1 2026, closing a stake of 6,347 shares — an estimated $485K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in BBIO in Q1 2022 and held it in 6 quarters. The position peaked at $3.73M in Q1 2022. 460 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining BridgeBio Pharma position as of Q1 2026 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 6,347 BridgeBio Pharma shares in Q1 2026, an estimated $485K.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in BridgeBio Pharma in Q1 2022 and held it in 6 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s BridgeBio Pharma position peaked at $3.73M in Q1 2022.
460 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2026, filed 11 May 2026.